Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia

Journal of the National Medical Association

Volumn 98, Issue 8, 2006, Pages 1273-1277

  Bolaman, Zahit ^a,b   Kadikoylu, Gurhan ^a,b   Özgel, Nihat ^a,b   Yenisey, Cigdem ^a,b  

^a Adnan Menderes University Medical Faculty ^*

^b ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

Atorvastatin; Coagulation; Homocysteine; Hypercholesterolemia

Indexed keywords

ANTITHROMBIN III; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; CREATINE KINASE; CYANOCOBALAMIN; D DIMER; FIBRINOGEN; FOLIC ACID; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN C; PROTEIN S; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; VON WILLEBRAND FACTOR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANXIETY DISORDER; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONSTIPATION; FEMALE; HEADACHE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERCHOLESTEROLEMIA; LEUKOCYTE COUNT; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; TURKEY (REPUBLIC);

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD COAGULATION; CORONARY DISEASE; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; TREATMENT OUTCOME;

EID: 33746700800     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Castelli WP. Epidemiology of coronary heart disease. The Framingham study. Am J Med. 1984;76:4-12.
2. Whiteman T, Hassouna HI. Hypercoagulable states. Hematol Oncol Clin North Am. 2000;14:355-377.
3. Wada H, Mori Y, Kaneko T, et al. Hypercoagulable state in patients with hypercholesterolemia: effect of pravastatin. Clin Ther. 1992;14:829-834.
4. Girolami A, Simioni P, Scarano L, et al. Venous and arterial thrombophilia. Haematologica. 1997;82:96-100.
5. Ruggeri ZM. Von Willebrand factor. Curr Opin Hematol. 2003;10:142-149.
6. Maresca G, Di Blasio A, Marchioli R, et al. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arterioscl Thromb Vasc Biol. 1999;19:1368-1377.
7. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary disease. N Engl J Med. 1997;337:230-236.
8. Scandian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
9. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
10. Mayer J, Eller T, Brauer P, et al. Effects of long term treatment with lovastatin on clotting system and blood platelets. Ann Hematol. 1992;64:196-201.
11. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction: JAMA. 1998;279:1643-1650.
12. White CM. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol. 1999;39:111-118.
13. Joukhadar C, Klein N, Prinz M, et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost. 2001;85:47-51.
14. Milionis HJ, Papakostas J, Kakafika A, et al. Comparative effects of atorvastatin, simvastatin and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol. 2003;43:825-830.
15. Executive summary of third report of the national cholesterol education program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
16. Summary of the second report of the National cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation an Treatment of High Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
17. Friedewald WT, Levy RI, Fredrikson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:449-502.
18. Dujovne CA, Harris WS, Altman R, et al. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol. 2000;85:350-353.
19. Crouse JR III, Frohlich J, Ose L, et al. Effects of high doses simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-1. Am J Cardiol. 1999;15:1476-1477.
20. Marais AD, Firth JC, Bateman ME, et al. Atorvastatin an effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997;17:1527-1531.
21. Koschinsky ML. Lipoprotein (a) and atherosclerosis: new perspectives on the mechanism of action and enigmatic lipoprotein. Curr Atheroscler Rep. 2005;7:389-395.
22. Alaupovic P, Heinonen T, Shurzinske L, et al. Effect of new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with eleveted serum cholesterol and triglyceride levels. Atherosclerosis, 1997;133:123-33.
23. Bickel C, Rupprecht HJ, Elankenberg S, et al. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol. 2002;82:25-31.
24. Mitropoulos KA, Armitage JM, Collins R, et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. Eur Heart J. 1997;18:235-241.
25. Colli S, Eligini S, Lalli M, et al. Vastatins tissue factor in cultured human macrophages: a novel mechanism of protection against atherothrombosis. Arterioscl Thromb Vasc Biol. 1997;17:265-272.
26. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost. 1991;66:67-79.
27. Wierzbicki AS, Lumb PJ, Semra Y, et al. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidemias. QJM. 1999;92.387-394.
28. Kadikoylu G, Yukselen V, Yavasoglu I, et al. Hemostatic effects of atorvastatin versus simvastatin. Ann Pharmacother. 2003;37:478-484.
29. Sotiriou CG, Cheng JW. Beneficial effects of statins in coronary artery disease beyond lowering cholesterol. Ann Pharmacother. 2000;34:1432-1439.
30. Kushiya F, Wada H, Ooi K, et al. Effects of atorvastatin on serum lipids, lipoproteins and hemostasis. Am J Hematol. 2005;78:1-6.
31. Tousoulis D, Antoniades C, Bosinakou E, et al. Effect of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart. 2005;91:27-31.
32. Broncel M, Marczyk I, Chojnowska-Jezierska J, et al. The comparison of simvastatin and atorvastatin effects on hemostatic parameters in patients with hyperlipidemia type II. Fol Merkuriusz Lek. 2005;18:380-384 (abstract).
33. Pokrovskaia EV, Gratsianskii NA, Vaulin NA, et al. Relationship between lipid lowering and changes of hemostasis and inflammation during use of statins in non-ST elevation acute coronary syndrome. Kardiologiia. 2004;44:40-45 (abstract).
34. Leibovitz E, Hazanov N, Frieman A, et al. Atorvastatin reduces fibrinogen levels in patients with severe hypercholesterolemia additional evidence to support the anti-inflammatory effects of statins. Isr Med Assoc J. 2004;6:456-459.
35. Eikelboom JW, Lonn E, Genest J Jr, et al. Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999;131:363-375.
36. McKinley MC. Nutritional aspects and possible pathological mechanisms of hyperhomocysteinaemia: an independent risk factor for vascular disease. Proc Nutr Soc. 2000;59:221-237.
37. Young IS, Woodside JV. Folate and Homocysteine. Curr Opin Clin Nutr Metab Care. 2000;3:427-432.
38. Makris M. Hyperhomocysteinemia and thrombosis. Clin Lab Haematol. 2000;22:133-143.
39. Navarro JF, Mora C, Muros M, et al. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis. Nephron Clin Pract. 2003;95:c128-c135.
40. Melenovsky M, Malik J, Wichterle D, et al. Comparison of the effects of atorvastatin a fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J. 2002;144:E6.
41. Sasaki S, Kuwahara N, Kunitomo K, et al. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol. 2002;89:386-389.